Clinically relevant doses of galunisertib were used to enhance the antitumor activity of anti‐PD‐L1 therapy (antimurine PD‐L1 clone), resulting in tumor regression and enhanced T‐cell activation in a murine colorectal cancer model [51]. Here, CD274 is linked to neoplasm.